Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 18, 2014 - Issue 11
Submit an article Journal homepage
655
Views
20
CrossRef citations to date
0
Altmetric
Reviews

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

Wen-Yue LiuThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, School of the First Clinical Medical Sciences, Wenzhou 325000, China
,
Sha HuangThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, School of the First Clinical Medical Sciences, Wenzhou 325000, China
,
Ke-Qing ShiThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, Institute of Hepatology, Wenzhou 325000, China
,
Chen-Chen ZhaoThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, School of the First Clinical Medical Sciences, Wenzhou 325000, China
,
Li-Li ChenThe First Affiliated Hospital of Wenzhou Medical University, Department of Intensive Care Unit, Wenzhou 325000, China
,
Martin BraddockGlobal Medicines Development, AstraZeneca R&D, Loughborough, UK
,
Yong-Ping ChenThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, Institute of Hepatology, Wenzhou 325000, China
,
Wen-Ke FengUniversity of Louisville School of Medicine, Alcohol Research Center, Department of Medicine, Louisville, KY, USA
&
Ming-Hua ZhengThe First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases, No. 2 Fuxue Lane, Wenzhou 325000, China+86 577 88078232; +86 577 88078262; [email protected];Wenzhou Medical University, Institute of Hepatology, Wenzhou 325000, China
, MD PhD show all
Pages 1305-1313 | Published online: 31 Jul 2014
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Introduction: Fibroblast growth factor 21 (FGF21) is one of the FGF family members that is produced mainly by tissues with high metabolic activity such as liver, pancreas, muscle and adipose tissue. The major function of FGF21 is to improve insulin sensitivity, ameliorate hepatic steatosis and enhance energy expenditure. Recently, several studies have reported a correlation between FGF21 and liver disease with numerous cross-sectional studies demonstrating significant correlation. This review will focus on the role of FGF21 in the pathogenesis of liver disease and its potential role as a biomarker and a new target for therapeutic intervention.

Areas covered: This review discusses cross-sectional studies and underlying mechanisms of FGF21 as an endocrine hormone in several liver diseases. Two major theories of ‘endoplasmic reticulum stress’ and ‘FGF21 resistance’ in particular are explained. Moreover, early functional detection and pharmacological effect of FGF21 for liver disease are also described.

Expert opinion: FGF21 can be a promising treatment in liver disease. However, still several problems are needed to be answered. The most important are whether different liver disease share common underlying mechanisms and the pharmacological effect in human with limited studies. Further studies are needed to explain the underlying mechanisms and develop potential therapeutic effect for human liver disease.

Acknowledgments

This work was supported by grants from the Scientific Research Foundation of Wenzhou, Zhejiang Province, China (H200 90014, Y20090269), Health Bureau of Zhejiang Province (2010KYB070), Research Foundation of Education Bureau of Zhejiang Province (Y201009942), Fresh Talent Program for Science and Technology Department of Zhejiang Province (2013R413018, 2013R413035 and 2013R413015), Research Funds for Tian Qing Liver Diseases (TQGB20120057) and Project of New Century 551 Talent Nurturing in Wenzhou. W-Y Liu, S Huang and K-Q Shi contributed equally to this work.

Notes

This box summarizes key points contained in the article.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,049.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.